MISSOURI BIOTECHNOLOGY ASSOCIATION - WHAT WE DO
Missouri Biotechnology Association (MOBIO) is the only statewide membership group that speaks with one voice to advance and champion the life sciences in Jefferson City, across the state, and in Washington, D.C. MOBIO represents most extensive and broadest cross-section of life science organizations including businesses, higher education, medical research, start-ups, agri-science and related firms involved in research, development, and commercialization of the life sciences. MOBIO serves to connect, develop, and advance the state’s bioscience community.
MOBIO members benefit from a strategic focus to support the enrichment and growth of the biosciences in Missouri through:
MOBIO connections make a difference, specializing in meaningful business-to-business engagements and bridging:
- A network of diversified thought leaders
- Business leaders with policymakers
- Entrepreneurs with investors
- Members to greater market potential
Members connect at regional, national, and international levels with science, education, and commercial networks to advance business and enrich the industry.
MOBIO is the catalyst, accelerating growth and leveraging high-value relationships for our vibrant life sciences community.
Science & Policy
MOBIO advocates for Missouri’s life sciences and technology sectors. Maintaining a sophisticated understanding of current dynamics, MOBIO serves as your trusted voice for bipartisan engagement and leadership within the Missouri State Capitol.
- MOBIO forges meaningful relationships between public and private sector leaders to:
- Defend companies large and small
- Obtain and safeguard public investment
- Secure state funding for Missouri's life science industry
The strength of MOBIO's collective voice consistently delivers a compelling message to advance pro-science, pro-business legislative policy.
MOBIO saves members real money, providing access to numerous partner organizations that offer significant discounts on relevant industry products and services.
- R & D
- Finance & Administration
- Facilities & Operations
- Communications & Data
All MOBIO members are entitled to preferred purchasing power. There is NO fee to participate.
MOBIO Member Highlight
Vertex Forward: Our journey in cystic fibrosis
In my time at Vertex, I have seen our team of scientists and researchers make great strides in our development of treatment options for the underlying cause of cystic fibrosis (CF), a rare, chronic and life-shortening genetic disease.
This journey first began more than 20 years ago in Vertex’s labs.
While addressing the dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein with a small molecule approach was deemed impossible by many, our commitment to helping patients with this devastating disease was unwavering.
Today, we have four medicines available to certain eligible people with CF.
But we won’t stop there.
While our current portfolio of therapies has the ability to treat up to 90% of people living with CF, we are devoted to reaching every person with the disease. We have set the bar high for ourselves, and I’ve remained amazed by the grit and tenacity our team brings each and every day to innovate, discover and test additional investigational medicines and combination therapies.
For example, we are partnering with Moderna on an investigational new type of messenger ribonucleic acid, or mRNA, therapy that we hope may help to treat the approximately 5,000 people who have no treatment options for the underlying cause of their disease.
To learn more about our journey in CF and our commitment to innovative science, watch this short video.
Join us for MOBIO's Breakthrough of the Month series, where we explore Missouri's new and sometimes hidden biotech industry.
This is a virtual learning platform for the greater life science community where we highlight and discuss novel discoveries, new business opportunities, and potential partnerships.
This is a FREE presentation that is open to those in the life-science community.
Are you interested in featuring your organization or discovery? Please reach out to us, via email.